Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis

摘要

Background: No randomized controlled trials have compared the efficacy of fingolimod or natalizumab as second-line treatment in patients with relapsing-remitting multiple sclerosis (RRMS).